Systemic antibacterial agents. Other -lactam antibiotics. Third-generation cephalosporins. Ceftriaxone
Ceftriaxone is a parenteral third-generation cephalosporin antibiotic with a prolonged action. Microbiology. The bactericidal activity of ceftriaxone is due to an inhibition of cell membrane synthesis.
Ceftriaxone-Darnitsa should be used for the treatment of infections whose pathogens are sensitive to ceftriaxone:
– pulmonary tract infections, especially pneumonia, as well as ear, throat, and nose infections;
– infections of the abdominal organs (peritonitis, biliary and gastrointestinal tract infections);
– renal and urinary tract infections;
– genital infections including gonorrhea;
– Bone, joint, soft tissue, skin, and wound infections;
– infections in patients with weakened immunity;
– disseminated Lyme disease (stage 2 and 3).
Postoperative prevention of infections in gastrointestinal tract, biliary tract, urinary tract surgeries, and during gynaecological procedures, but only in cases of potential or known contamination.
When the medicine is prescribed, the official guidelines for antibiotic therapy and, in particular, the recommendations for the prevention of antibiotic resistance should be followed.
Adults and children over 12 years old: 1–2 g of ceftriaxone once per day (every 24 hours) should be prescribed. In severe infections or infections whose pathogens have only moderate sensitivity to ceftriaxone, the daily dose can be increased to 4 g.
Neonates, infants, and children under 12 years old.
The recommended doses for once daily use are provided below.
Neonates under 2 weeks: 20–50 mg/kg body weight once per day, the daily dose should not exceed 50 mg/kg body weight. There are no differences in determining the dose for full-term and preterm infants.